Last edition
News about "IQVIA"
Lupin Launches Liraglutide Injection in US
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.
IQVIA | 04/10/2025 | By Dineshwori
Lupin Receives Approval from US FDA for Rivaroxaban for Oral Suspension
Lupin’s Rivaroxaban will be manufactured at the company’s Chhatrapati Sambhajinagar facility.
IQVIA | 01/10/2025 | By Dineshwori | 128
Lupin Receives Tentative Approval from US FDA for its HIV treatment tablets
Lupin has received tentative US FDA approval for Bictegravir, Emtricitabine and Tenofovir Alafenamide Tablets to treat HIV, bioequivalent to Gilead’s Biktarvy, for adults and paediatric patients over 25 kg.
IQVIA | 25/09/2025 | By Dineshwori
NVIDIA Teams Up with Industry Leaders to Accelerate Genomics and Drug Discovery
Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, are using the latest NVIDIA technologies to develop solutions that will help advance human health.
IQVIA | 15/01/2025 | By Aishwarya | 341
IQVIA Market Reflection Report - JB Pharma
IQVIA Market Reflection Report pins JB Pharma as the fastest growing Pharma Company with a growth rate of over 20% for the month of August 2022
IQVIA | 22/09/2022 | By Sudeep Soparkar | 911
Opportunities and challenges need to be harnessed in digital ecosystem
A vibrant digital health ecosystem can not only ease access to health services, making ubiquitous and streamlined, but also reduce out of pocket expenses in the long term and healthcare industry players should start assessing the opportunities and risks they could face, say experts from data and analytics major IQVIA.
IQVIA | 04/05/2022 | By Sudeep Soparkar | 759
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy